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The development of cancer has been an extensively re-
searched topic over the past few decades. Although great 
strides have been made in cancer prevention, diagnosis, 
and treatment, there is still much to be learned about can-
cer’s micro-environmental mechanisms that contribute to 
cancer formation and aggressiveness. Macrophages, lym-
phocytes which originate from monocytes, are involved in 
the inflammatory response and often dispersed to areas of 
infection to fight harmful antigens and mutated cells in 
tissues. Macrophages have a plethora of roles including 
tissue development and repair, immune system functions, 
and inflammation. We discuss various pathways by which 
macrophages get activated, various approaches that can 
regulate the function of macrophages, and how these ap-





Macrophages are important cells of the immune system. They 
are derived from monocytes which enter various tissues and 
differentiate into macrophages. In the immune response, they 
use phagocytosis, a process in which the macrophages engulf 
pathogens, to protect the human body from disease. In addition 
to macrophages’ importance to the general functions of the 
immune system, they also play various roles in cancer. These 
macrophages, or tumor-associated macrophages (TAMs), 
interact with cancer cells to cause phagocytosis and lysis of 
tumor cells. On the other hand, TAMs have also been discov-
ered to be an integral part of the tumorigenic pathway. The 
balance of cytokines and other molecular signals determines 
the role of these TAMs and thus it is important to study them 
closely. However, it is important to note that approximately 80% 
of studies show an association between TAMs and pro-
tumorigenic effects while only 10% of studies show the oppo-
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site effect.  
Before delving into TAMs’ function in cancer, it is important to 
understand the general cancer process. Cancer can be broken 
into three distinct stages. In the first stage, cancerous cells 
invade an area’s surrounding tissues and blood vessels; this 
area is referred to as the primary site. In the second stage, the 
cancer cells begin to move to secondary sites through the cir-
culatory system. In the third and final stage, the cancer cells 
invade the secondary site’s surrounding tissues and blood ves-
sels. This cycle can then repeat yielding tertiary sites and so 
forth. Once the primary site is established, tumor development 
is spurred by angiogenesis. Hanahan and Weinberg (2000), 
created a model that lays out the six properties that a tumor 
acquires while growing. These properties include an ability to 
replicate endlessly, angiogenesis, evasion of apoptosis, creat-
ing its own growth signals, insensitivity to growth inhibitors, and 
tissue invasion and metastasis. A seventh property, tumor mi-
croenvironment inflammation, was later added to the model 
(Hanahan and Weinberg, 2000; Mantovani, 2009) (Fig. 1). Here 
we discuss the mechanisms by which macrophages get acti-
vated and their important role in tumor progression.  
 
TUMOR ASSOCIATED MACROPHAGES AND RELATED 
MOLECULES 
 
Two different types of phenotypes for macrophages have been 
described; these include: M1 and M2. The M1 phenotype is 
associated with active microbial killing while the M2 phenotype 
is associated with angiogenesis and wound repair. TAMs can 
typically be identified by low expression of tumor necrosis fac-
tors (TNF) and high expression of IL-1 and IL-6. Specifically M1 
macrophage polarization is caused by interferon gamma (IFN-
gamma) and TNF- secretion by T helper 1 (Th1) lymphocytes 
or natural killer (NK) cells (Gordon, 2003; Martinez et al., 2009; 
Murray and Wynn, 2011). Interferon (IFNs) or toll-like receptor 
(TLR) signals can produce the M1 phenotype through the 
STAT1 signaling pathway. M1 macrophages also produce 
chemical attractants, such as pro-inflammatory cytokines, inter-
leukin-12 (IL-12), IL-1, and IL-6 (Heusinkveld and van der 
Burg, 2011; Porta et al., 2011). M2 macrophages, on the other 
hand, are activated by Th2. Th2 releases several cytokines, 
such as IL-4, IL-10, and IL-13, to activate the M2 macrophages 
(Gordon, 2003; Murray and Wynn, 2011). The M2 macrophage 
phenotype is caused by IL-4 and IL-13 via the STAT6 signaling 
pathways. In addition, Kruppel-like factor 4 (KFL4) works in 
conjunction with STAT6 to produce M2 genes, while inhibiting 
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Fig. 1. The major steps involved in cancer. This model depicts essen-
tial steps during cancer progression. These steps include conti-
nuous replication, developing new blood vessels, self- sufficiency of 
growth signals, insensitivity to growth inhibitors, formation of in-
flammatory microenvironment, promotion of tissue invasion and 




the M1 phenotype, the M2 phenotype can be divided into 3 
more categories: M2a, M2b, and M2c. M2a is differentiated by 
IL-4 and IL-13 while M2b by immune complexes. M2c is diffe-
rentiated by IL-10 and also plays a role in immunosuppression 
and tissue remodeling (Hagemann et al., 2009). Furthermore, it 
has been shown that Th1 cytokines produce M1 macrophages 
while M2 macrophages play a role in Th1 adaptive immunity 
suppression, resolution of inflammation, parasite protection, 
wound healing promotion, angiogenesis, and tissue remodeling 
(Biswas and Mantovani, 2010).  
Some of the most potent macrophage activators of metasta-
sis involved in Lewis lung carcinoma lead to the production of 
IL-6 and TNF- through the activation of essential-to-
metastasis TLR2 and TLR6 (Chiodoni et al., 2010; Kim et al., 
2009). These macrophages are recruited to tumor cells by the 
production of monocyte chemotactic protein (MCP), macro-
phage-colony stimulating factor (M-CSF), vascular endothelial 
growth factor (VEGF), angiopoietin 1 (ANG1), and ANG2. In 
addition to macrophage recruitment, VEGF, ANG1, and ANG2 
play roles in promoting angiogenesis (Pollard, 2004). Anti-
inflammatory molecules, such as IL-4, IL-10, transforming 
growth factor beta 1 (TGF-1), and prostaglandin E2 (PGE2) 
produced by tumor cells cause macrophages to attain the M2 
phenotype. Adding IL-10 in vitro inhibits production of proin-
flammatory cytokines and chemokines (Kim et al., 1995). IL-10 
also reduces surface expression of major histocompatibility 
complex II (MHCII) and co-stimulatory molecules CD80 and 
CD86 resulting in immunosuppression (Moore et al., 2001). 
Additionally, IL-10 interacts with IL-4 to cause Arginase-1 ex-
pression in macrophages (Lang et al., 2002). The source of this 
IL-10 is not yet known, but PGE2, which is produced by tumor 
cells, has been shown to effect TAM polarization along with 
EP4 receptors (Akaogi et al., 2004; Heusinkveld et al., 2011; 
Kambayashi et al., 1995). TLRs, such as TLR2 and TLR4, 
cause cytokines to become proinflammatory and thus polarize 
TAMs. The production of proteases by TAMs, such as uroki-
nase type plasminogen activator (uPA) and MMP-9, further 
enhance tumor invasion by breaking down the basement 
membrane and remodeling the stromal matrix (Huang et al., 
2002; Stetler-Stevenson and Yu, 2001; Wang et al., 2005). 
Epidermal growth factor (EGF), TGF-, IL-8, and TNF- all play 
roles in the migration of tumor cells in addition to protecting the 
tumor cells by providing them with proliferative and anti-apoptotic 
signals. TGF-1 derived from macrophages also caused 
greater expression of matrix metalloproteinase 9 (MMP-9) in 
glioma stem-like cells which has been shown to increase 
tumor cell invasiveness (Ye et al., 2012). MMP-9 also causes 
the release of VEGF-A, a precursor to angiogenesis. In addition, 
M2 macrophages express a truncated fibronectin isoform, mi-
gration-stimulation factor (MSF), which has a large chemotactic 
effect on tumor cells. Depletion studies conducted by Denardo 
et. al and Joyce and Pollard showed reduced levels of metas-
tasis as well (DeNardo et al., 2009; Joyce and Pollard, 2009). 
Furthermore, macrophages that are attracted to inflammation or 
tissue breakdown sites have been shown to promote tumorige-
nesis by synthesizing estrogens (Figs. 2 and 3).  
Looking further into VEGF, it has been determined that it is 
an angiogenic factor that triggers angiogenesis and lymphangi-
ogenesis. Angiogenic and lymphangiogenic factors include 
VEGF-A, VEGF-C, VEGF-D, and MMP that all bind to their re-
spective coordinating receptors and play roles in enhancing 
endothelial cell proliferation, migration, and tube-like formation 
(Giraudo et al., 2004; Wu et al., 2012). MMP has also been 
shown to mediate VEGF-A levels in some studies. Specifically, 
MMPs are proteolytic enzymes tasked with the degradation of 
proteins within the extracellular matrix. They regulate many cell 
behaviors within the tumor microenvironment (Egeblad and 
Werb, 2002). 
The importance of lymphangiogenesis must not be unders-
tated because it plays a large role in tumor stability and growth 
even though it occurs second to angiogenesis in a tumor. Lym-
phangiogenesis exposes the tumor to immune cells leading to 
lymphatic metastasis and without it, the tumor would likely stop 
growing and be destroyed (Kurahara et al., 2012). Lymphangi-
ogenesis is typically induced by VEGF-A and VEGF C/D bind-
ing with VEGFR-2 and VEGFR-3 receptors. In addition, tissue 
inflammation in tumors has been shown to expand lymph 
nodes and lead to increased lymphangiogenesis and lymphoid 
hyperplasia. Inhibition of M-CSF has been shown to suppress 
tumor lymphangiogenesis since it plays a role in VEGF-A/C 
secretion. Interestingly, endothelial nitric oxide synthase (eNOS) 
and IL-6 also regulate lymphangiogenesis (Ji, 2011) (Fig. 3). 
Research has shown that there is a positive correlation be-
tween the number of TAMs and advanced tumor progression 
and metastasis. Many tumors show overexpression of M-CSF 
and when down-regulated, there is a decrease in macrophage 
activity. Knocking out MCP has led to lower levels of macro-
phages and decreased tumor progression as well. These data 
demonstrate a clear relationship between TAMs and tumorige-
nesis. Surprisingly, further overexpression of MCP has shown 
that at a certain point, M1 macrophages are attracted to the site 
causing cytotoxic effects on the tumor cells (Shirabe et al., 2011). 
In addition to the decrease in macrophage activity due to the 
downregulation of M-CSF, vascularization is also reduced. 
Without vascularization, larger tumors struggle to grow due to 
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insufficient amounts of oxygen causing hypoxic regions. TAMs 
compensate for this effect by congregating in these areas caus-
ing upregulation of certain transcription factors that lead to the 
expression of various growth factors, cytokines, and other sig-
naling molecules resulting in angiogenesis (Obeid et al., 2013). 
These transcription factors cause secretion of VEGF and basic 
fibroblast growth factor (bFGF) which promote the proliferation 
and maturation of endothelial cells (Lamagna et al., 2006; Si-
veen and Kuttan, 2009). TAM created proteases, such as 
MMPs, plasmin, and urokinase plasminogen activator, degrade 
and remodel the extracellular matrix leading to further angioge-
nesis (Siveen and Kuttan, 2009).  
The majority of research indicates increased levels of TAM 
activity result in a negative prognosis. The M1 phenotype is 
usually present during early stages of tumor development while 
the M2 phenotype is associated with more advanced tumors. In 
addition, compounds such as VEGF and M-CSF allow for tu-
mor development to progress by recruiting macrophages to the 
tumor site and initiating angiogenesis and lymphangiogenesis.  
 
TUMOR MICROENVIRONMENT AND MACROPHAGES 
 
The tumor microenvironment is a niche that has been shown to 
affect tumor activity and outcome. It is created the moment the 
tumor becomes attached to a site and encompasses the extra-
cellular matrix surrounding the tumor cell and any non-cancerous 
cells that happen to reside in the targeted organ (Fig. 2). 
Colony stimulating factor 1 (CSF1) and chemokine ligand 2 
(CCL2) in the blood recruit monocytes that become TAMs in 
the tumor microenvironment, a process called intraepithelial 
Fig. 2. The tumor microenvironment. It is 
created the moment the tumor becomes 
attached to a site and encompasses the 
extracellular matrix surrounding the tumor 
cell and any non-cancerous cells. This mi-
croenvironment is composed of endothelial 
cells, stromal cells, bone marrow derived 
cells, macrophages and TIE2-expressing 
monocytes and myeloid derived suppressor 
cells. 
Fig. 3. Macrophage functions in the tumor
microenvironment with special emphasis on
immunosuppression, metastasis, lymphangi-
ogenesis and angiogenesis. During immuno-
suppression, TAM generated molecules pre-
vent the accumulation of cytotoxic T cells
(anti-tumorigenic cells). During metastasis,
tumor cells secrete soluble factors that prime
specific cells such as macrophages that help
in seeding tumor cells at distant locations. In
hypoxic areas, TAMs and TEMs (Tie2-expressing
monocytes) upregulate several angiogenic
factors that promote angiogenesis. During lym-
phangiogenesis, TAMs secrete various fac-
tors that initiate the formation of lymphatics.
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neoplasia. In addition to CSF-1, the cytokines VEGF and PDGF 
and chemokines CCL2, CCL5, and CCL8 all attract monocytes 
to the tumor microenvironment (Allavena et al., 2008; Goede et 
al., 1999; Mantovani et al., 2008; Pollard, 2004) (Fig. 3). It may 
be important to note that CCL2 upregulation is caused by a 
RAS mutation (Qing et al., 2012). Consequently, overexpres-
sion of CSF-1 has led to a poor prognosis in patients with 
breast, endometrial, and ovarian cancers (Pollard, 2004; 2009). 
CSF-1 also interacts with IL-6 causing the maturation of den-
dritic cells creating a tumor microenvironment in which the tu-
mor’s progression to metastasis is easier. Interestingly, CSF-1 
in a trans-membrane form on the tumor surface has been 
shown to activate macrophages that kill tumor cells. Trans-
membrane CSF-1 with higher concentrations of IL-4, IL-12, IL-
13, and granulocyte-macrophage colony-stimulating factor (GM-
CSF) causes dendritic cells to mature as well; however, this 
leads to the presentation of tumor antigens to cytotoxic T cells 
resulting in the killing of the tumor (Pollard, 2004). By producing 
growth factors such as VEGF, TAMs assist the transition from 
intraepithelial neoplasia to an early carcinoma. While the carci-
noma develops, TAMs continue to be activated allowing them 
to promote angiogenesis, cell invasion, intravasation, and im-
munosuppression. These abilities are due to the fact that TAMs 
are immobilized in hypoxic or necrotic regions of human tumors 
and, thus, TAMs upregulate hypoxia inducible factor 1 (HIF-
1) and HIF-2 (Raica et al., 2009). TAMs specifically promote 
angiogenesis with the help of Tie2-expressing monocytes 
(TEMs) and tumor cells themselves by upregulating angiogenic 
growth factors and enzymes to stimulate endothelial cells in the 
healthy surrounding areas to proliferate, migrate, and differen-
tiate into the vessels in the tumor site (Coffelt et al., 2009). Evi-
dence has shown that the tumor microenvironment is immuno-
suppressive causing the tumor to go unnoticed by the immune 
response. For example, M-CSF has been shown to render 
unable macrophages’ ability to present antigens. TAMs also 
produce immunomodulatory cytokines and growth factors that 
assist in immunosuppression (Galdiero et al., 2013). Typically, 
this occurs at the primary site or locations where lymphocytes 
mature, such as lymph nodes. TAMs also show immunosup-
pressive activity through their modulation of TGF-, iNOS, Argi-
nase-1, IDO, and IL-10 (Hagemann et al., 2006; Mantovani and 
Sica, 2010; Sica et al., 2000; Zhao et al., 2012a; 2012b). For 
instance, Arginase-1 and iNOS expression causes T cell sup-
pression in mouse models of breast cancer (Bronte and Zano-
vello, 2005; Chang et al., 2001; Doedens et al., 2010; Movahe-
di et al., 2010). TAMs have also been shown to express B7-H1 
in hepatocellular carcinoma, B7-H4 in ovarian and lung cancers, 
and B7-H3 in lung cancer on tumor cell surfaces which make it 
easier for the tumor cells to not be susceptible to immune re-
sponse (Chen et al., 2012). These cytokines change the ex-
pression of genes by regulating NF-B, a transcription factor, in 
addition to STAT1 and STAT3. Thus, the recruitment of antitu-
morigenic cells is downregulated resulting in a decrease of 
essential components of antigen-presenting. This inability to 
perform these functions affects the cytokine and protein profile 
of the tumor microenvironment, which plays a large role in de-
termining the phenotype of local phagocytes (Coffelt et al., 
2009). 
 
TUMOR ASSOCIATED MACROPHAGE REGULATION 
BY TRANSCRIPTION FACTORS 
 
It has been reported that some transcription factors also regu-
late TAM functions. Nuclear factor-B (NF-B) is activated by 
TNF-, IL-1, and IKK. NF-B refers to a family of transcription 
factors that plays a role in inflammation and immunity. NF-B 
operates by causing the expression of pro-inflammatory cyto-
kines, chemokines, and angiogenic factors (Porta et al., 2011). 
Thus NF-B is an important part of the regulation of TAM func-
tion. Transcription factors for NF-B include Re1A (p65), c-Rel, 
RE1B, p50, and p52. Out of those transcription factors, only 
Re1A, Re1B, and c-Rel can activate gene transcription (Hage-
mann et al., 2009). NF-B is activated primarily by IKK (Mae-
da et al., 2005). Another activator of NF-B is hypoxia, a com-
mon marker of tumors (Rius et al., 2008). Activating NF-B in 
inflammatory macrophages releases cytokines, interleukins, 
and TNF-. It has been shown in breast cancer cells that secre-
tion of TNF-, activation of NF-B, and presence of JNK leads 
to a more invasion and tumor progression. Inhibition of NF-B 
also directly leads to lower levels of VEGF, impeding angioge-
nesis. IB is a prominent inhibitor of NF-B and results in 
decreased tumor formation when it is overexpressed (Pikarsky 
et al., 2004). Interestingly, it has also been shown that low le-
vels of NF-B activation results in macrophages acquiring the 
M2 phenotype. A theory explaining this discrepancy is that NF-
B may have a different role depending on the stage and loca-
tion of the TAMs within a tumor. This was shown in epithelial 
cells when IKK was knocked out and inflammation decreased, 
while in myeloid cells, inflammation was increased (Fong et al., 
2008; Lawrence et al., 2001). In contrast, some reports indicate 
that targeted NF-B activation can induce apoptosis of hepato-
cytes while decreasing tumor size, suggesting multiple roles of 
NF-B (Greten et al., 2004; Hagemann et al., 2008; Luedde et 
al., 2007; Maeda et al., 2005; Naugler et al., 2007; Swain and 
Arezzo, 2008). 
 
TUMOR ASSOCIATED MACROPHAGE REGULATION 
BY HYPOXIA 
 
There have been many studies examining the effect of hypoxia 
on TAMs within the tumor microenvironment (Fig. 4). Low le-
vels of tissue oxygenation induce TAM differentiation of macro-
phages (Erler et al., 2009; Shen et al., 2012). HIF activation has 
been determined to promote tumorigenesis due to higher levels 
of angiogenesis, cell proliferation, and TAM differentiation. 
There are 3 types of HIFs: HIF-1, -2, and -3. HIF-1 is an 
important part of TAM response to hypoxia due to its ubiquitous 
expression and its induction of many hypoxia-inducible genes 
(Rankin and Giaccia, 2008). VEGF and CXCL12 are depen-
dent on HIF-1 (Knowles and Harris, 2007). HIF-1 also regu-
lates CSF-1. NF-B can be modulated to regulate HIF-1 
(Murdoch et al., 2004). Furthermore, deletion of HIF-1 has 
shown reduced tumor growth (Shen et al., 2012). Hypoxia 
causes HIF-1 to upregulate genes such as VEGF, bFGF, IL-
1, IL-8, cyclooxygenase 2 (COX2), MMP-7, MMP-9, MMP-12, 
and ANG-1 which lead to macrophages assuming the M2 phe-
notype and formation of a vascular system and malignant tran-
sition (Murdoch and Lewis, 2005; Murdoch et al., 2008). In-
creased HIF-2 expression in macrophages leads to angioge-
nesis and worse survival (Leek et al., 2002). Accordingly, TAMs 
with the highest levels of HIF-2 indicate high-grade breast 
cancers (Leek et al., 2002). Without HIF-1, the suppressive 
capabilities of TAMs were reduced while without HIF-2, there 
was less TAM recruitment in inflammatory hepatocellular and 
colon carcinoma models (Imtiyaz et al., 2010). 
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Fig. 4. Functions of tumor associated macrophages during tumor 
cell migration and invasion. Macrophages migrate to hypoxic areas 
and in turn stimulate angiogenesis with the help of various angi-
ogenic factors. TAMs also promote invasion through the secretion 
of proteases. Several growth factors and chemokines aid in promot-
ing migration of tumor cells to the vessels, and TAMs can break 
down the basement membrane as well to promote intravasation. 
 
 
TAMs AS POTENTIAL DIAGNOSTIC AND PROGNOSTIC 
MARKERS  
 
TAMs in breast tumor microenvironments typically express four 
surface markers; receptors for Fc portion of IgG and C3, HLA-
DR antigen, and a macrophage-associated antigen (Steele et 
al., 1985). CD68, the human homolog of macrosialin, has been 
widely used as a pan-macrophage marker. There are many 
antibodies that recognize CD68 including Ki-M6, Ki-M7, Y2/131 
and Y1/82A, EBM11, KP1, Ki-M1P, and PG-M1 (Gottfried et al., 
2008). Increased CD68 expression has been shown to corre-
late with high vascularity and nodal metastasis and reduced 
recurrence-free and survival in human breast cancer (Jubb et 
al., 2010; Leek et al., 1996). Mahmoud et al., showed that in-
creased CD68 markers predicted worse breast cancer-specific 
survival and shorter disease-free interval (Mahmoud et al., 
2011). Other markers such as estrogen receptors (ER), proge-
sterone receptor (PR), and human epidermal growth factor 2 
(HER2) give a positive prognosis and were specifically de-
signed to aid in therapy. However, it is not known how TAMs 
are associated with ER/PR/HER2 and thus more research 
must be conducted on the relationship between them before 
suggesting it as a possible treatment option. TAMs have also 
been shown to interfere with chemotherapy for breast cancer 
by releasing chemo-resistance factors or regulating the drug-
resistance of cancer stem cells. 
Since CD68 staining stains both M2 and M1 macrophages, 
CD68 cannot be used by itself to predict overall survival (Jubb 
et al., 2010; Mahmoud et al., 2011; Tsutsui et al., 2005). Thus 
other TAM-associated markers such as CD163, VEGF, HIFs 
markers, proliferating cellular nuclear antigen (PCNA), ferritin 
light chain (FTL), and CCL-18 have been proposed as possible 
options to use for detection of TAMs along with CD68. CD163 
has been shown to be primarily expressed by M2 macrophages 
and thus has been associated with worse characteristics (Me-
drek et al., 2012). VEGF and EGFR are involved in macro-
phage infiltration in human breast cancer (Leek et al., 2000). 
VEGF, as noted previously, recruits more macrophages to the 
tumor microenvironment. TAMs with PCNA have been asso-
ciated with high-grade, HR-negative breast cancers with an 
increased risk of recurrence and decreased overall survival in 
human breast cancers (Campbell et al., 2010; Mukhtar et al., 
2011a). FTL stored in M2 macrophages indicates an aggres-
sive phenotype in node-negative breast cancer patients. 
CCL18 is abundantly produced by breast cancer TAMs and is 
associated with metastasis and reduced patient survival. The 
counts predicted disease stage, histological grade, and lymph 
node and distant metastasis (Chen et al., 2011). Recent studies 
have indicated that CCL18 is a new and promising biomarker 
for cancer diagnosis and treatment. 
 
POSSIBLE TREATMENT STRATEGIES USING 
VARIOUS PROTEINS AND SMALL MOLECULES  
 
Tumor suppressors act in a variety of ways including inducing 
cell-cycle arrest, senescence, or apoptosis. Retinoblastoma 
protein (Rb) plays a role in cell cycle control, differentiation, and 
inhibition of oncogenic transformation in addition to activation of 
NF-B pathway. Promyelocytic leukemia protein (PML) plays a 
role in tumorigenesis, DNA damage, senescence, apoptosis, 
and protein degradation. P53 plays a role in ribosome biogene-
sis, aging control, cell cycle arrest, and apoptosis. P53 also 
regulates MCP-1/CCL2. ARF, interestingly, is one of the most 
frequently mutated genes in human cancer (Sharpless, 2005). 
ARF activates p53 and inhibits ribosomal RNA processing and 
transcriptional factors that induce proliferation. ARF activates 
p53 by displacing Mdm2 in the nucleolus (Pomerantz et al., 
1998; Stott et al., 1998), and inhibits ribosomal RNA processing 
and transcriptional factors that induce proliferation (Kuo et al., 
2003; Martelli et al., 2001; Qi et al., 2004; Sugimoto et al., 
2003). ARF has a protective effect against viral infection by 
interacting with cell proliferation nucleophosmin (NPM) and 
activating dsRNA-dependent protein kinase (PKR) (Garcia et 
al., 2006). ARF may even modulate M2 polarization of macro-
phages. ARF-deficient macrophages show less leukocyte re-
cruitment and decreased ability to produce pro-inflammatory 
properties. E2F1 is increased in ARF-deficient mice which have 
been shown to be anti-inflammatory and immunosuppressive 
which impaired the signaling of the NF-B pathway. On the 
other hand, it has been shown to be deleted in some cancers 
thus more research must be conducted to further elucidate 
ARF’s function and effectiveness as a target for possible gene 
therapy. 
Other methods have been investigated in order to interrupt or 
decrease macrophage recruitment to tumor microenvironments. 
Leuschner et al. used lipid nanoparticles containing siRNA to 
interrupt the CCL2-CCR2 interaction in order to disrupt macro-
phage recruitment. Using this method, they showed that the 
TAM infiltration was decreased (Leavy, 2011; Leuschner et al., 
2011; Shantsila et al., 2011). Deletion of the CSFR1 gene re-
duced macrophage recruitment as well but only in resident 
tissue macrophages under normal conditions (MacDonald et al., 
2010). Denardo et al. showed that using the PlexxiKon inhibitor, 
which inhibits CSFR1, along with cKit and PDGFR improved 
overall survival in mouse mammary carcinoma models (Denar-
do et al., 2011; Hume and MacDonald, 2011). Dijkgraaf et al. 
showed that blocking NF-B signaling stopped platinum che-
motherapy’s effect of increased IL-6 and PGE2 causing more 
M2 differentiation. Thus anti-IL-6 therapy is another recom-
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mended route for therapies (Dijkgraaf et al., 2013). Other ap-
proaches include inhibition of GM-CSF in vivo and decreased 
VEGF and CCL-5 as ways to reduce monocyte recruitment 
(Bayne et al., 2012; Elbarghati et al., 2008; Pylayeva-Gupta et 
al., 2012). Hystidine-rich glycoprotein (HRG) has been shown 
to have anti-tumor mechanisms in breast, pancreatic, and fibro-
sarcoma murine models. Although there were no significant 
differences in TAM accumulation, the tumor volume was signifi-
cantly decreased. Thus, HRG may be reducing M2 differentia-
tion as levels of CXCL9 and IFN- are increased, which is a 
characteristic for M1 macrophages (Rolny et al., 2011). CD40 
has also been used to make macrophages attain the classical 
M1 phenotype (Beatty et al., 2011; Chan et al., 2010). 
One way to directly target macrophage phenotype differentia-
tion in tumor microenvironments is by targeting the NF-B 
pathway. This was done by inhibiting IKK, the main activator 
of NF-B in murine models. This led to reduced tumor volume 
(Hayakawa et al., 2009). Another method to reduce tumor sur-
vival is to reprogram the TME to impair tumor growth only. This 
can be accomplished by using antibodies such as ipilimumab 
which targets CTLA-4 activating T cells, nivolumab, lambroli-
zumab, and CD40 targeted antibodies. Nivolumab targets the 
PD1 receptor causing apoptosis, while lambrolizumab is a 
blocking antibody for the PD1 ligand (Hamid et al., 2013; Hodi 
et al., 2010; Hwu, 2010; Restifo et al., 2012; Sharma et al., 
2011; Vonderheide and Glennie, 2013; Wolchok et al., 2013). 
Combining these strategies may reduce tumor cells’ evasion of 
the immune response and help destroy them. All of these me-
thods have been somewhat effective and resulted in greater 
overall survival. 
Therapeutic treatments for hepatocellular carcinoma (HCC) 
that target TAMs have focused on inhibition of recruitment 
and/or polarization of M2 macrophages, inhibition of angiogenic 
and tissue remodeling, and inhibition of TAMs’ immunosup-
pressive effects. Clodronate-encapsulated liposomes or ami-
nobisphosphonates knock down macrophages in vivo but have 
also been shown to reduce angiogenesis and tumor progres-
sion. Researchers have also attempted to prevent M2 polariza-
tion or to convert them from M2 to M1. This was attempted by 
using the CpG immunostimulatory oligonucleotide and anti-IL-
10 receptor which caused macrophages to turn from M2 to M1 
(Vicari et al., 2002). TAMs lacking STAT6 also display an M1 
phenotype which can lead to further possibilities to prevent M2 
polarization. CCL2/MCP-1 were discovered to have antitumor 
effects by using suicide gene therapy as well (Kakinoki et al., 
2010; Tsuchiyama et al., 2008). 
 
BISPHOSPHONATES AS THERAPEUTIC MODALITIES 
 
Bisphosphonates are stable inorganic analogs of pyrophos-
phonate in which the central oxygen atom is replaced with a 
carbon atom. They are common in the treatment of many bone 
diseases such as cancer-induced bone disease, Paget’s dis-
ease, and osteoporosis. There are two types of bisphospho-
nates: nitrogen-containing (N-BP) and non-nitrogen containing 
(non N-BP) which are characterized by the presence of a nitro-
gen atom on the R2 side chain (Rodan and Fleisch, 1996; 
Stresing et al., 2007; Winter and Coleman, 2009). Non N-BPs 
inhibit the conversion of ATP to ADP which causes mitochon-
drial dysfunction leading to apoptosis. N-BPs alter protein pre-
nylation by inhibiting farnesyldiphosphonate (FPP) synthase 
which is important for the mevalonate pathway in eukaryotic 
cells (Green, 2002; Luckman et al., 1998; Monkkonen et al., 
2006; Moreau et al., 2007; Stern, 2007). 
To target TAMs in breast cancer, N-BPs are utilized. They in-
terfere with the process of PTHrP, prostaglandin-E, and inter-
leukins stimulating RANKL causing osteoclast progression 
which in turn causes bone resorption leading to release of TGF-
 helping tumor cells proliferate and grow. Specifically, they 
interfere with the bone resorption step in this cycle (Mundy, 
2002). N-BPs have also been shown to directly affect tumors by 
reducing tumor cell proliferation, adhesion, migration, invasion, 
and angiogenesis while increasing apoptosis (Boissier et al., 
1997; 2000; Fromigue et al., 2000; Hiraga et al., 2004; Senaratne 
et al., 2000; 2002; van der Pluijm et al., 1996). Biphosphonates 
can also directly target macrophages due to their similarities 
with osteoclasts. Using them has been shown to inhibit macro-
phage proliferation, migration, invasion, and cause apoptosis. 
They can also inhibit MMP-9 as shown in vivo and in vitro and 
inhibit VEGF, and thereby angiogenesis and polarization to M2 
macrophages. This effect, in turn, resulted in decreased tumor 
sizes and growth (Coscia et al., 2009; Gabrilovich and Nagaraj, 
2009; Mantovani et al., 2002). Other studies have shown the 
usage of N-BPs have resulted in similar results, presenting a 




Much research has been completed elucidating the effects of 
TAMs in cancer. It has been shown that TAMs have a generally 
pro-tumorigenic effect. With this knowledge, it is possible to 
determine new therapies targeting TAMs and using them 
against the tumor to reduce volume and stunt tumor growth. A 
few proteins such as Rb, PML, and p53 act as tumor suppres-
sors allowing for modulation of the proteins in an attempt to 
curb tumor growth. A viable and promising option is to mod-
ulate ARF, one of the most commonly mutated genes in cancer, 
to activate p53. This method has been shown to be promising, 
but more research must be completed. Directly targeting TAMs 
by reducing monocyte recruitment is another feasible option. 
This may be accomplished by interrupting the CCL2-CCR2 
interaction. Another method to accomplish this is to downregu-
late GM-CSF, a crucial component used to recruit monocytes 
to the tumor. Similarly, it may be more feasible to control M2 
differentiation by upregulating HRG or CD-40 to cause macro-
phages to assume the M1 phenotype, associated with antitu-
morigenic effects. The NF-B pathway can also be targeted by 
inhibiting it with IKK reducing M2 differentiation. N-BPs have 
also been introduced as a novel idea to decrease tumor growth. 
N-BPs were shown to interfere in tumor cell proliferation, adhe-
sion, migration, invasion, and angiogenesis while increasing 
apoptosis. In addition, N-BPs can inhibit MMP-9 and VEGF 
resulting in less M2 polarization and decreased angiogenesis.  
Research on each of the aforementioned methods seems to 
indicate that they are all viable methods in the fight against 
cancer. More research must be completed to confirm their ef-
fects and usefulness in fighting tumors by attacking TAMs. It is 
clear, however, that progress is being made and novel methods 
to fighting cancer are on the horizon.  
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